CD274 and esophageal cancer: Taken esophageal cancer as an example, several studies have demonstrated that pembrolizumab plus chemotherapy is not a cost-effective option for advanced esophageal cancer in the US and China, regardless of PD-L1 expression status [17, 21, 22].